GEN Exclusives

More »

GEN News Highlights

More »
Sep 20, 2011

BI and Nuevolution Leverage Chemetics Platform in Drug Discovery Collaboration

  • Boehringer Ingelheim (BI) and Nuevolution inked a drug discovery collaboration focused on exploiting the latter’s Chemetics® platform to screen for drug candidates against BI targets. Under terms of the deal BI will pay the Danish firm an up-front fee, research funding, and development milestones.

    Nuevolution describes its Chemetics platform as a  convergent fragment-based lead discovery technology that combines wet chemistry and molecular biology to enable the synthesis and selection of ligands from millions to billions of drug-like compounds in a single test tube. The firm claims that in contrast with current, low-throughput fragment based methods that apply NMR and crystallography, which can typically only screen hundreds to a few thousand fragments against a target, the Chemetics technology harnesses the best aspects of high-throughput screening and fragment-based screening to sample potentially billions of fragments. The overall process allows more than 100 million molecules to screened against a given target in just 2–3 days, using only micrograms of target material and nanograms of library material.

    Critically, each compound within a Chemetics library is linked to a strand of DNA encoding the synthetic history and chemical structure of the small molecule produced from a split-and-mix synthesis process. This DNA tag provides essentially single-molecule detection by allowing amplification and sequencing for hit/lead identification from in vitro affinity screening of compound libraries of immense complexity.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »